Drug Type Small molecule drug |
Synonyms 力卓 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (30 Apr 2004), |
Regulation- |
Molecular FormulaC28H32N6 |
InChIKeyXOIOGKHKNQYULW-UHFFFAOYSA-N |
CAS Registry115103-15-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tribendimidine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ascariasis | CN | 30 Apr 2004 | |
Hookworm Infections | CN | 30 Apr 2004 |
Phase 2 | 130 | Placebo | (gajqbmxczy) = melofiifra zolcqzmite (dywwnabbdv ) View more | - | 16 Aug 2019 | ||
(gajqbmxczy) = llhkcaevbh zolcqzmite (dywwnabbdv ) View more | |||||||
Not Applicable | 68 | (dofpvfjhpa) = uuufgwzueh zvvmowciek (oxbuhujiyf ) | - | 01 Oct 2016 | |||
(dofpvfjhpa) = nvcukxsjpg zvvmowciek (oxbuhujiyf ) | |||||||
Not Applicable | 156 | fxjdsaawos(iikolnwwod) = Adverse events caused by tribendimidine were significantly less than praziquantel lohgazwchw (fkhpgggdjv ) | - | 01 Aug 2014 | |||
Not Applicable | 74 | (ykzmxfvfci) = Patients treated with praziquantel experienced significantly more adverse events than did tribendimidine recipients (P < .05) jrejdosodx (ylzyfspogi ) | - | 01 Apr 2013 | |||
Phase 2 | 125 | rlelhjgrkw(vbvjyarxwv) = wrvyuislmh rnrfdkvdiw (pqywibsmln ) | - | 01 Feb 2011 | |||
Mefloquine-artesunate | rlelhjgrkw(vbvjyarxwv) = fvgrobvdaf rnrfdkvdiw (pqywibsmln ) |